

Board of Governors of the Federal Reserve System, December 26, 2002.

**Jennifer J. Johnson,**

*Secretary of the Board.*

[FR Doc. 02-33046 Filed 12-31-02; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 28, 2003.

**A. Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166-2034:

1. *Century Bancshares, Inc.*, Gainesville, Missouri; to acquire 24.8 percent of Ozarks Heritage Financial Group, Inc., Gainesville, Missouri, and thereby indirectly acquire Community First Financial Corporation and its subsidiary, Bank of Plato, both of Plato, Missouri.

2. *Ozarks Heritage Financial Group, Inc.*, Gainesville, Missouri; to become a bank holding company by acquiring 100 percent of Community First Financial Corporation, Plato, Missouri, and thereby indirectly acquire Bank of Plato, Plato, Missouri.

Board of Governors of the Federal Reserve System, December 27, 2002.

**Jennifer J. Johnson,**

*Secretary of the Board.*

[FR Doc. 02-33140 Filed 12-31-02; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL RESERVE SYSTEM

### Federal Open Market Committee; Domestic Policy Directive of November 6, 2002

In accordance with § 271.25 of its rules regarding availability of information (12 CFR part 271), there is set forth below the domestic policy directive issued by the Federal Open Market Committee at its meeting held on November 6, 2002.<sup>1</sup>

The Federal Open Market Committee seeks monetary and financial conditions that will foster price stability and promote sustainable growth in output. To further its long-run objectives, the Committee in the immediate future seeks conditions in reserve markets consistent with reducing the federal funds rate to an average of around 1¼ percent.

By order of the Federal Open Market Committee, December 23, 2002.

**Vincent R. Reinhart,**

*Secretary, Federal Open Market Committee.*

[FR Doc. 02-33141 Filed 12-31-02; 8:45 am]

**BILLING CODE 6210-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Meeting of the President's Council on Bioethics on January 16-17, 2003

**AGENCY:** The President's Council on Bioethics, HHS.

**ACTION:** Notice.

**SUMMARY:** The President's Council on Bioethics will hold its ninth meeting, at which it will discuss, among other things the ethics of organ procurement

<sup>1</sup> Copies of the Minutes of the Federal Open Market Committee meeting on November 6, 2002, which includes the domestic policy directive issued at the meeting, are available upon request to the Board of Governors of the Federal Reserve System, Washington, D.C. 20551. The minutes are published in the Federal Reserve Bulletin and in the Board's annual report.

and the role of the U.S. Food and Drug Administration (FDA) in public policy related to biotechnology. Subjects discussed at past Council meetings include: human cloning; embryonic stem cell research; the patentability of human organisms; extratherapeutic powers to enhance or improve human mood, memory, and muscles; research to extend the human lifespan; current and projected uses of preimplantation genetic diagnosis and screening (PGD); new techniques for choosing the sex of children; prospects for inheritable genetic modification (IGM); international models of biotech regulation; and the use of stimulants and related drugs to affect the behavior of children.

**DATES:** The meeting will take place Thursday, January 16, 2003, from 9 a.m. to 5:15 p.m. ET; and Friday, January 17, 2003, from 8:30 a.m. to 12:30 p.m. ET.

**ADDRESSES:** Grand Hyatt Washington at Washington Center, 1000 H Street, NW, Washington, DC 20001.

**Public Comments:** The meeting agenda will be posted at <http://www.bioethics.gov>. Members of the public may submit written statements for the Council's records. Please submit statements to Ms. Diane Gianelli, Director of Communications (tel. 202/296-4669 or e-mail [info@bioethics.gov](mailto:info@bioethics.gov)). The public may also express comments during the time set aside for this purpose, beginning at 11 a.m. ET, on Friday, January 17, 2003. Comments will be limited to no more than five minutes per speaker or organization. Please give advance notice of such statements to Ms. Gianelli at the phone number given above, and be sure to include name, affiliation, and a brief description of the topic or nature of the statement.

**FOR FURTHER INFORMATION CONTACT:** Diane Gianelli, 202/296-4669, or visit <http://www.bioethics.gov>.

Dated: December 23, 2002.

**Dean Clancy,**

*Executive Director, The President's Council on Bioethics.*

[FR Doc. 02-33116 Filed 12-31-02; 8:45 am]

**BILLING CODE 4161-90-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary; Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI)

and the Assistant Secretary for Health have taken final action in the following case:

*Michael E. Ganz, M.D., Case Western Reserve University:* Based on the report of an investigation conducted by Case Western Reserve University (CWRU Report) and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Dr. Ganz, Associate Professor of Medicine, CWRU, engaged in scientific misconduct by falsification and fabrication of research in grant application R01 DK058674-01A2, "The role of protein kinase C and shuttling proteins in diabetic kidney disease," submitted to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH).

Specifically, PHS found that Dr. Ganz engaged in scientific misconduct by:

(1) Falsifying Figure 16 in NIH grant application R01 DK058674-01A2 by claiming that photomicrographs of glomeruli were from a streptozotocin model of induced diabetes in rat, while the photomicrographs were actually from tissue of human or other primate origin;

(2) Falsifying Figure 16 of this NIH grant application by claiming that six photomicrographs all represented glomeruli from different animals, whereas they actually were from only three different glomeruli, with each glomerulus being shown in two images with different orientations and/or magnifications; and

(3) Falsifying and fabricating documents, purportedly showing the source of the falsified Figure 16 in the NIH grant application, which the Respondent provided to the CWRU inquiry committee.

The research was significant because it was designed to develop a therapy to prevent the progressive glomerular hypertrophy and matrix deposition that occur with the renal disease associated with diabetes in animals and humans.

Dr. Ganz has entered into a Voluntary Exclusion Agreement in which he has voluntarily agreed for a period of five (5) years, beginning on December 18, 2002:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government referred to as "covered transactions" as defined in 45 CFR part 76 (Debarment Regulations); and

(2) To exclude himself from serving in any advisory capacity to PHS including but not limited to service on any PHS

advisory committee, board, and/or peer review committee, or as a consultant.

**FOR FURTHER INFORMATION CONTACT:**

Director, Division of Investigative Oversight, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

**Chris B. Pascal,**

*Director, Office of Research Integrity.*

[FR Doc. 02-33079 Filed 12-31-02; 8:45 am]

**BILLING CODE 4150-31-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**[Program Announcement 02060]**

**National Cancer Prevention and Control Program Notice of Availability of Funds; Amendment 2**

A notice announcing the availability of fiscal year (FY) 2002 funds for cooperative agreements for the National Cancer Prevention and Control Program (NCCPCP) was published in the **Federal Register** April 23, 2002, Volume 67, Number 78, pages 19932-19950. The notice is amended as follows:

Delete Sections A. through F., page 19932, first column, through page 19934, second column. The information provided in these sections will be replaced in an open season announcement that will be published annually.

Page 19934, first and second column, section "G.2 Availability of Funds", delete all specific dollar amounts listed. New dollar amounts will be published in the annual open season announcement.

Page 19935, first column, section "G.2.d Funding Preference", delete the phrase "There are no funding preferences applicable to this component" and replace it with the phrase "Funding preference may be given to applicants from the prior year's applications who were considered Approved but Unfunded (ABU). Those applicants will be named in the annual open season announcement."

Page 19937, first column, section "G.4.a.(3)(b)", delete the phrase "letters of support must be (in a separate tabbed section of the application) that indicate the nature and extent of existing or planned collaborative support" and replace it with the phrase "letters of support that indicate the nature and extent of existing or planned collaborative support may be included in the appendices."

Page 19937, third column, section "G.4.a(7)(b) Travel", first paragraph, correct the typographical error "NCCPCP" to read "NCCCP."

Page 19938, first column, section "G.4.b", second paragraph, after the phrase "For each proposal, the following information should be submitted:" insert the phrase "An Executive Summary consisting of a brief summary of proposed project, including goals, objectives, and description of who will complete the work."

Page 19938, second column, section "G.5.a", delete the phrase "(1 of 2)" from the header. Delete the first sentence "In addition to the general guidance provided in Section J-Other Requirements, the first two required progress reports should include a description of:" and replace it with "In addition to the guidance provided in Section J-Progress Reports 1 and 2 should include a description of:"

Page 19939, second column, section "G.6.a.(3)(f)", delete this entire section.

Page 19939, second column, section "H.2. Availability of Funds", delete all specific dollar amounts listed. New dollar amounts will be published in the annual open season announcement.

Page 19939, third column, section "H.2.b.(1)", reads "Not less than 60 percent of cooperative agreement funds must be spent for screening, tracking, follow-up \* \* \*" Delete the term "tracking" and replace it with "case management."

Page 19940, third column, section "H.4.Content", second paragraph, delete "\* \* \* 65 double spaced pages \* \* \*" and replace it with "\* \* \* 53 double spaced pages \* \* \*"

Page 19941, second column, section "H.4.a.(4)(f) Overall measures of success/effectiveness", second paragraph, delete "\* \* \* fiscal year 2002-2003 \* \* \*" and replace with "\* \* \* proposed project year \* \* \*"

Page 19941, third column, section "H.4.a.(5)(a) Travel", insert the following requirements:

H.4.a.(5)(a)[5] Up to two staff members to participate in the NCCDPHP Annual Chronic Disease Conference (4 days).

H.4.a.(5)(a)[6] On alternating years, starting with 2003, up to two staff members to participate in the National Cancer Conference in Atlanta (5 days).

Page 19943, third column, section "I.1. Eligible Applicants", third paragraph, add the following sentences: "However, after five consecutive years of NPCR funding as planning, applicants are expected to have achieved progress toward the Enhancement level of operations. If applicants have not been able to achieve